Biondvax Pharmaceuticals Ltd BVXV

NAS: BVXV | ISIN: US09073Q1058   8/11/2023
0,690 USD (+7,81%)
(+7,81%)   8/11/2023

10 april 2024 · Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG · Persbericht

12 maart 2024 · Scinai leadership to attend BIO-Europe Spring 2024 · Persbericht

13 februari 2024 · Scinai Welcomes Liat Halpert as Head of Business Development and Sales · Persbericht

4 januari 2024 · Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds · Persbericht

21 november 2022 · BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco · Persbericht

3 november 2022 · BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference · Persbericht

2 november 2022 · BiondVax provides plan to address Nasdaq compliance · Persbericht

11 oktober 2022 · BiondVax to present at LD Micro Investor Conference in Los Angeles · Persbericht

30 september 2022 · BiondVax announces financial plans to support its ongoing NanoAb pipeline development · Persbericht

20 september 2022 · BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19 · Persbericht

8 september 2022 · BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference · Persbericht

25 augustus 2022 · BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update · Persbericht

10 augustus 2022 · BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy · Persbericht

Mijn selecties